<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39390544</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6963</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>BMC health services research</Title><ISOAbbreviation>BMC Health Serv Res</ISOAbbreviation></Journal><ArticleTitle>Introduction of a hexavalent vaccine containing acellular pertussis into the national immunization program for infants in Peru: a cost-consequence analysis of vaccination coverage.</ArticleTitle><Pagination><StartPage>1216</StartPage><MedlinePgn>1216</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1216</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12913-024-11684-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Infant vaccination coverage rates in Peru have declined in recent years, exacerbated by the COVID-19 pandemic. Introduction of the fully-liquid diphtheria, tetanus, and acellular pertussis (DTaP)-inactivated polio vaccine (IPV)-hepatitis B (HB)-Haemophilus influenzae type B (Hib) hexavalent vaccine (DTaP-IPV-HB-Hib) in Peru's infant National Immunization Program may help improve coverage. We evaluated costs and healthcare outcomes, including coverage, of switching from a pentavalent vaccine containing whole-cell pertussis component (DTwP-HB-Hib) plus IPV/oral polio vaccine (IPV/OPV) to the hexavalent vaccine for the primary vaccination scheme (2, 4 and 6 months).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The analysis was performed over a 5-year period on a cohort of children born in Peru in 2020 (N = 494,595). Four scenarios were considered: the pentavalent plus IPV/OPV scheme (S1); replacing the pentavalent plus IPV/OPV scheme with the hexavalent scheme (S2); expanded delivery of the pentavalent plus IPV/OPV scheme (S3); expanded delivery of the hexavalent scheme (S4). Vaccine coverage and incidence of adverse reactions (ARs) were estimated using Monte Carlo simulations and previous estimates from the literature. Cases of vaccine-preventable diseases were estimated using a Markov model. Logistical and healthcare costs associated with these outcomes were estimated. Impact of key variables (including coverage rates, incidence of ARs and vaccine prices) on costs was evaluated in sensitivity analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall cost from a public health payer perspective associated with the pentavalent plus IPV/OPV vaccine scheme (S1) was estimated at $56,719,350, increasing to $61,324,263 (+ 8.1%), $59,121,545 (+ 4.2%) and $64,872,734 (+ 14.4%) in scenarios S2, S3 and S4, respectively. Compared with the status quo (S1), coverage rates were estimated to increase by 3.1% points with expanded delivery alone, and by 9.4 and 14.3% points, if the hexavalent vaccine is deployed (S2 and S4, respectively). In both scenarios with the hexavalent vaccine (S2 and S4), pertussis cases would also be 5.7% and 8.7% lower, and AR rates would decrease by 32%. The cost per protected child would be reduced when the hexavalent vaccine scheme. Incidence of ARs was an important driver of cost variability in the sensitivity analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Implementation of the hexavalent vaccine in Peru's National Immunization Program has a positive public health cost consequence.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seinfeld</LastName><ForeName>Janice</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Videnza Consultores, Lima, Peru. jseinfeld@videnza.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Videnza Consultores, Calle Los Manzanos 296, San Isidro, Lima, Peru. jseinfeld@videnza.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobrevilla</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Videnza Consultores, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosales</LastName><ForeName>María Laura</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Videnza Consultores, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibañez</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Videnza Consultores, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munayco</LastName><ForeName>César</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Videnza Consultores, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Delia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Videnza Consultores, Lima, Peru.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Health Serv Res</MedlineTA><NlmUniqueID>101088677</NlmUniqueID><ISSNLinking>1472-6963</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018073">Haemophilus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015721">Diphtheria-Tetanus-Pertussis Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022681">Diphtheria-Tetanus-acellular Pertussis Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010568" MajorTopicYN="N" Type="Geographic">Peru</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018073" MajorTopicYN="Y">Haemophilus Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073887" MajorTopicYN="Y">Vaccination Coverage</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="Y">Immunization Programs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="Y">Vaccines, Combined</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015721" MajorTopicYN="N">Diphtheria-Tetanus-Pertussis Vaccine</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022681" MajorTopicYN="N">Diphtheria-Tetanus-acellular Pertussis Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014917" MajorTopicYN="N">Whooping Cough</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Haemophilus influenzae type b</Keyword><Keyword MajorTopicYN="N">Cost-consequence analysis</Keyword><Keyword MajorTopicYN="N">Diphtheria-tetanus-pertussis</Keyword><Keyword MajorTopicYN="N">Hepatitis B</Keyword><Keyword MajorTopicYN="N">Hexavalent vaccination</Keyword><Keyword MajorTopicYN="N">Polio</Keyword><Keyword MajorTopicYN="N">Vaccination coverage gap</Keyword><Keyword MajorTopicYN="N">Vaccination coverage rate</Keyword></KeywordList><CoiStatement>All authors are employees of Videnza Consultores who were contracted by Sanofi to conduct this research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39390544</ArticleId><ArticleId IdType="pmc">PMC11468117</ArticleId><ArticleId IdType="doi">10.1186/s12913-024-11684-8</ArticleId><ArticleId IdType="pii">10.1186/s12913-024-11684-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maman K, Zöllner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11(9):2132–41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4635899</ArticleId><ArticleId IdType="pubmed">26075806</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26(6):496–500.</Citation><ArticleIdList><ArticleId IdType="pubmed">17529866</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Salud, MINSA. Technical Norm Nª196-2022-MINSA. 2023</Citation></Reference><Reference><Citation>World Health Organization: Global Routine Immunization Strategies and Practices (GRISP): A Companion Document to the Global Vaccine Action Plan (GVAP). 2016 Avilable at: https://www.who.int/teams/immunization-vaccines-and-biologicals/essential-programme-on-immunization/implementation/global-routine-immunization-strategies-and-practices-(grisp). Accessed 11 Jun 2023.</Citation></Reference><Reference><Citation>United Nations Children’s Fund (UNICEF). Peru: WHO and UNICEF estimates of immunization coverage: 2021 revision. https://data.unicef.org/resources/immunization-country-profiles/. Accessed 11 Jun 2023.</Citation></Reference><Reference><Citation>Instituto Nacional de Estadística e Informática. Perú: Encuesta Demográfica y de Salud Familiar - ENDES 2019. https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Endes2019/. Accessed 11 Jun 2023.</Citation></Reference><Reference><Citation>Instituto Nacional de Estadística e Informática. Perú: Encuesta Demográfica y de Salud Familiar - ENDES 2020. https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Lib1795/ . Accessed 11 Jun 2023.</Citation></Reference><Reference><Citation>Instituto Nacional de Estadística e Informática: Perú: Encuesta Demográfica y de Salud Familiar - ENDES 2022. 2023, https://www.gob.pe/institucion/inei/informes-publicaciones/4233597-peru-encuesta-demografica-y-de-salud-familiar-endes-2022. Accessed 13 Sep 2023.</Citation></Reference><Reference><Citation>Mesa de Concertación para la Lucha contra la Pobreza. Perú: El caso del niño con poliovirus derivado de vacuna tipo 1 en la provincia de Datem del Marañón - Departamento de Loreto. 2023.</Citation></Reference><Reference><Citation>Organización Panamericana de la Salud: Poliomielitis. https://www.paho.org/es/temas/poliomielitis . Accessed 15 Aug 2024.</Citation></Reference><Reference><Citation>Nunes MC, Madhi SA. Review of a new fully liquid, hexavalent vaccine: Hexaxim. Expert Opin Biol Ther. 2013;13(4):575–93.</Citation><ArticleIdList><ArticleId IdType="pubmed">23441818</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Tafalla M, Hanssens L, Dolhain J. A review of Haemophilus influenzae disease in Europe from 2000–2014: challenges, successes and the contribution of hexavalent combination vaccines. Expert Rev Vaccines. 2017;16(11):1095–105.</Citation><ArticleIdList><ArticleId IdType="pubmed">28971707</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Salud de Chile. Programa nacional de inmunizaciones. Calendario de vacunación 2022. https://www.minsal.cl/programa-nacional-de-inmunizaciones . Accessed 11 Jun 2023.</Citation></Reference><Reference><Citation>Ministerio de Salud Pública y Bienestar Social: La vacuna hexavalente acelular llega para proteger a los niños de Paraguay contra 6 enfermedades. 2023, https://pai.mspbs.gov.py/la-vacuna-hexavalente-acelular-llega-para-proteger-a-los-ninos-de-paraguay-contra-6-enfermedades/#:~:text=Nuevo%20esquema&amp;text=Paraguay%20es%20el%20cuarto%20pa%C3%ADs,ahora%20Paraguay%20en%20el%202023. Accessed 17 Aug 2024.</Citation></Reference><Reference><Citation>UNICEF El Salvador: El Ministerio de Salud incluye nuevas vacunas dentro del esquema nacional de vacunación 2023 con el apoyo de UNICEF. 2023, https://www.unicef.org/elsalvador/comunicados-prensa/ministerio-de-salud-incluye-nuevas-vacunas-dentro-de-esquema-nacional. Accessed 17 Aug 2024.</Citation></Reference><Reference><Citation>Seinfeld J, Rosales ML, Sobrevilla A, López Yescas JG. Economic assessment of incorporating the hexavalent vaccine as part of the National Immunization Program of Peru. BMC Health Serv Res. 2022;22(1):651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9109284</ArticleId><ArticleId IdType="pubmed">35570278</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero M, Góngora DS, Caicedo ML, Benchabane D, Lopez JG. Cost-minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim®) in the Colombian expanded program on immunization. Value Health Reg Issues. 2021;26:150–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34474265</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivera I, Grau C, Dibarboure H, Torres JP, Mieres G, Lazarov L, Alvarez FP, Yescas JGL. Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine. BMC Health Serv Res. 2020;20(1):295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147015</ArticleId><ArticleId IdType="pubmed">32272920</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile A, Giglio N, Castellano V, López J, Dibarboure H. Vaccination in children under 1 year with pertussis component in the context of the global initiative for the eradication of Poliomyelitis in Argentina: economic analysis. Revista Chil De infectología. 2021;38(2):224–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">34184714</ArticleId></ArticleIdList></Reference><Reference><Citation>de Salud M. MINSA. Repositorio Único Nacional de Información en Salud - Reunis. 2021. https://drive.minsa.gob.pe/s/qGjApnEJxeCdE4q. Accessed 11 Jun 2023.</Citation></Reference><Reference><Citation>O’Ryan M, Calvo AE, Espinoza M, Vega N, Lagomarcino AJ, López Castillo H, Puentes E, Macina D. Parent reported outcomes to measure satisfaction, acceptability, and daily life impact after vaccination with whole-cell and acellular pertussis vaccine in Chile. Vaccine. 2020;38(43):6704–13.</Citation><ArticleIdList><ArticleId IdType="pubmed">32888742</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke-Deelder E, Suharlim C, Chatterjee S, Brenzel L, Ray A, Cohen JL, McConnell M, Resch SC, Menzies NA. Impact of campaign-style delivery of routine vaccines: a quasi-experimental evaluation using routine health services data in India. Health Policy Plan. 2021;36(4):454–63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128004</ArticleId><ArticleId IdType="pubmed">33734362</ArticleId></ArticleIdList></Reference><Reference><Citation>Serum Institute of India Pvt Ltd. Diphtheria, Tetanus, Pertussis (whole cell), Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine Adsorbed (product insert). 2010.</Citation></Reference><Reference><Citation>Sanofi Pasteur. Imovax Polio suspension for injection in multidose vial. Poliomyelitis vaccine (inactivated) (product insert). 2017.</Citation></Reference><Reference><Citation>Sanofi Pasteur. Hexaxim suspension for injection. Diphtheria, tetanus, pertussis (acellular, component), hepatitis b (andr), Poliomyelitis (inactivated) and haemophilus influenzae type b conjugate vaccine (adsorbed) (product insert). 2018.</Citation></Reference><Reference><Citation>Serum Institute of India Pvt Ltd. Poliomyelitis Vaccine (oral): Bivalent type 1 and 3 (product insert). 2014.</Citation></Reference><Reference><Citation>Secretaria De Salud: Manual de eventos supuestamente atribuibles a la vacunaciόn o immunizaciόn. 2014, https://www.gob.mx/cms/uploads/attachment/file/287240/ESAVI_2014.pdf . Accessed 13 Sep 2023.</Citation></Reference><Reference><Citation>Zent O, Arras-Reiter C, Broeker M, Hennig R. Immediate allergic reactions after vaccinations–a post-marketing surveillance review. Eur J Pediatr. 2002;161(1):21–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11808876</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602527</ArticleId><ArticleId IdType="pubmed">29413255</ArticleId></ArticleIdList></Reference><Reference><Citation>de Ministerio. Salud Pública de Cuba: Ficha técnica de Heberpenta. 2010.</Citation></Reference><Reference><Citation>Patterson J, Kagina BM, Gold M, Hussey GD, Muloiwa R. Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: a systematic review. Vaccine. 2018;36(40):6007–16.</Citation><ArticleIdList><ArticleId IdType="pubmed">30143272</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen O, Saldaña A, Cerda J, Abarca K. Seguridad en vacunas: descripción de Los eventos adversos notificados Al Sistema De vigilancia en Chile, 2014 a 2016. Rev Chil Infect. 2019;36(4):461–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31859770</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafack JG, De Serres G, Kiely M, Gariépy MC, Rouleau I, Top KA. Risk of recurrence of adverse events following immunization: a systematic review. Pediatrics 2017;140(3):e20163707.</Citation><ArticleIdList><ArticleId IdType="pubmed">28847985</ArticleId></ArticleIdList></Reference><Reference><Citation>Minsterio de Salud Perú. Centro Nacional de Epidemiologia, Prevencion y Control de Enfermedades. Epidemiological surveillance. Avilable at: https://www.dge.gob.pe/portalnuevo/salas-situacionales/sala-de-situacion-nacional/#tab-content-2</Citation></Reference><Reference><Citation>Instituto Nacional de Estadística e Informática. Estadísticas de Economía - ENDES 2022. https://www.inei.gob.pe/estadisticas/indice-tematico/economia/#url . Accessed 11 Jun 2023.</Citation></Reference><Reference><Citation>Banco Central de Reserva del Perú. Informe de la Encuesta Mensual de Expectativas Macroeconómicas: Febrero 2022. 2022. https://www.bcrp.gob.pe/estadisticas/encuesta-de-expectativas-macroeconomicas.html . Accessed 11 Jun 2023.</Citation></Reference><Reference><Citation>Superintendecia de Banca. Seguros Y AFP República del Perú. Cotización de oferta y demanda tipo de cambio promedio ponderado. https://www.sbs.gob.pe/app/pp/sistip_portal/paginas/publicacion/tipocambiopromedio.aspx. Accessed 11 Jun 2023.</Citation></Reference><Reference><Citation>Organização Pan-Americana da Saúde (OPAS): Vacunas: Fondo Rotatorio. 2020, https://www3.paho.org/hq/index.php?option=com_docman&amp;view=list&amp;format=html&amp;layout=default&amp;slug=vacunas-9980&amp;Itemid=270⟨=pt#gsc.tab=0 . Accessed 13 Sep 2023.</Citation></Reference><Reference><Citation>Organização Pan-Americana da Saúde (OPAS): Precios del Fondo Rotatorio. 2023, https://www.paho.org/es/tag/precios-fondo-rotatorio?topic=4823&amp;d%5Bmin%5D=2015-01-15&amp;d%5Bmax%5D=2023-08-15 . Accessed 13 Sep 2023.</Citation></Reference><Reference><Citation>Happe LE, Lunacsek OE, Kruzikas DT, Marshall GS. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J. 2009;28(2):98–101.</Citation><ArticleIdList><ArticleId IdType="pubmed">19148039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson KN, Wallace AS, Sodha SV, Daniels D, Dietz V. Assessing strategies for increasing urban routine immunization coverage of childhood vaccines in low and middle-income countries: a systematic review of peer-reviewed literature. Vaccine. 2016;34(46):5495–503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5309783</ArticleId><ArticleId IdType="pubmed">27692772</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre-Boza F, San Martín PP, Valenzuela BMT. How were DTP-related adverse events reduced after the introduction of an acellular pertussis vaccine in Chile? Hum Vaccin Immunother. 2021;17(11):4225–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828142</ArticleId><ArticleId IdType="pubmed">34495813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed H, Atomsa A. Assessment of child immunization coverage and associated factors in Oromia regional state, eastern Ethiopia. Sci Technol Arts Res J. 2013;2(1):36–41.</Citation></Reference><Reference><Citation>Chavez Y. Factores que influyen en el abandono del calendario de vacunación en madres de niños menores de 5 años. Lima: Universidad San Martín de Porres; 2017. Available at: https://repositorio.usmp.edu.pe/handle/20.500.12727/2692 . Accessed 11 Jun 2023.</Citation></Reference><Reference><Citation>Girmay A, Dadi AF. Full Immunization coverage and associated factors among children aged 12–23 months in a hard-to-reach areas of Ethiopia. Int J Pediatr. 2019;2019:1924941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6556785</ArticleId><ArticleId IdType="pubmed">31263502</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib MA, Soofi S, Cousens S, Anwar S, Haque NU, Ahmed I, Ali N, Tahir R, Bhutta ZA. Community engagement and integrated health and polio immunisation campaigns in conflict-affected areas of Pakistan: a cluster randomised controlled trial. Lancet Glob Health. 2017;5(6):e593–603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5439031</ArticleId><ArticleId IdType="pubmed">28495264</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MM, Vargas-Zambrano JC, Coudeville L. How did the adoption of wP-pentavalent affect the global paediatric vaccine coverage rate? A multicountry panel data analysis. BMJ Open. 2022;12(4):e053236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8981334</ArticleId><ArticleId IdType="pubmed">35379619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732148</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosky SK, Davis KL, Krishnarajah G. Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States. Hum Vaccin Immunother. 2017;13(11):2494–502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5703402</ArticleId><ArticleId IdType="pubmed">28881166</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljunid SM, Al Bashir L, Ismail AB, Aizuddin AN, Rashid S, Nur AM. Economic impact of switching from partially combined vaccine Pentaxim® and hepatitis B to fully combined vaccine Hexaxim® in the Malaysian National Immunization Program. BMC Health Serv Res. 2022;22(1):34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8734051</ArticleId><ArticleId IdType="pubmed">34986870</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>